Mumbai-based Sun Pharma Ltd said it received an abbreviated new drug application (ANDA) approval from US Food and Drug Administration (USFDA) to market its levetiracetam injection which is generic version of Keppra injection,.
This levetiracetam injection 100 mg/ml packaged in 500 mg/5ml single use vials is equivalent to UCB's Keppra injection 100 mg/ml. Annual sale in the US for levetiracetam injection is estimated at $85 million, Sun Pharma said in a regulatory filing.
Levetiracetam injection is used in adjunctive therapy for the treatment of partial onset seizures in adults with epilepsy. This injection is an alternative for patients when oral administration is temporarily not feasible.
On Thursday, Sun Pharma shares ended 0.6% down at Rs1,690 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.88% up at 17,616 points.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
